Literature DB >> 16004173

Rare case of fatal yellow fever vaccine-associated viscerotropic disease.

Gregg Gerasimon1, Kristie Lowry.   

Abstract

This report describes a case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) that occurred after vaccination in a 22-year-old female. Our patient presented with a clinical syndrome of fever, headache, nausea, and vomiting, which quickly progressed to multiorgan failure and ultimately death on hospital day 4. YEL-AVD is an extremely rare condition reported only a few times in the literature. The yellow fever vaccine is a known stimulus of systemic inflammation in the body. A mild subclinical viremia develops, which results in a persistent and robust T-helper-cell-dependent antibody response with long-lasting immune protection. The very rare patient may have an aberrant response to the 17D vaccine strain, causing the multiple organ system failure seen in YEL-AVD. Predisposing host factors that contribute to YEL-AVD are not yet known. Treatment for YEL-AVD is supportive. To the authors' knowledge, this patient was the first to have YEL-AVD as a result of standard US military vaccination protocols.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16004173     DOI: 10.1097/01.SMJ.0000157537.11806.DC

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  12 in total

1.  Live virus vaccines in transplantation: friend or foe?

Authors:  Charlotte M Verolet; Klara M Posfay-Barbe
Journal:  Curr Infect Dis Rep       Date:  2015-04       Impact factor: 3.725

2.  Production and characterization of vaccines based on flaviviruses defective in replication.

Authors:  Peter W Mason; Alexandr V Shustov; Ilya Frolov
Journal:  Virology       Date:  2006-05-18       Impact factor: 3.616

Review 3.  Yellow fever: a reemerging threat.

Authors:  Christina L Gardner; Kate D Ryman
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

Review 4.  Wanted, dead or alive: new viral vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Antiviral Res       Date:  2009-09-04       Impact factor: 5.970

5.  Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Authors:  Mark D Gershman; J Erin Staples; Adwoa D Bentsi-Enchill; J Gabrielle Breugelmans; Glacus S Brito; Luiz Antonio Bastos Camacho; Pascale Cottin; Cristina Domingo; Anna Durbin; Joaquim Gascon; Fouzia Guenaneche; Edward B Hayes; Zsuzsanna Jelenik; Alena Khromava; Reinaldo de Menezes Martins; Mario Masana Wilson; Nathalie Massy; Abdulsalami Nasidi; Matthias Niedrig; Adam Sherwat; Theodore Tsai; Anna Vilella; Mary Elizabeth Wilson; Katrin S Kohl
Journal:  Vaccine       Date:  2012-05-04       Impact factor: 3.641

6.  Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG.

Authors:  Mark K Slifka; Erika Hammarlund; Matthew W Lewis; Elizabeth A Poore; Jon M Hanifin; Kieren A Marr; Douglas Hecox; Ian J Amanna
Journal:  Transplantation       Date:  2013-05-15       Impact factor: 4.939

7.  Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever.

Authors:  Birgit Schäfer; Georg W Holzer; Alexandra Joachimsthaler; Sogue Coulibaly; Michael Schwendinger; Brian A Crowe; Thomas R Kreil; P Noel Barrett; Falko G Falkner
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

8.  Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.

Authors:  Anna H Roukens; Darius Soonawala; Simone A Joosten; Adriëtte W de Visser; Xiaohong Jiang; Kees Dirksen; Marjolein de Gruijter; Jaap T van Dissel; Peter J Bredenbeek; Leo G Visser
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

9.  Yellow fever virus vaccine-associated deaths in young women.

Authors:  Stephen J Seligman
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

Review 10.  Yellow fever vaccine-associated viscerotropic disease: current perspectives.

Authors:  Roger E Thomas
Journal:  Drug Des Devel Ther       Date:  2016-10-12       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.